THE BASIC PRINCIPLES OF LDN-27219 CANCER TREATMENT RESEARCH

A person notably attention-grabbing compound is LDN-27219. When most tTG inhibitors are built to bind into the protein crosslinking Energetic web site, LDN-27219 as an alternative binds to the nucleotide binding pocket of your enzyme although it is in its shut-state conformation, and stabilizes that conformation to forestall crosslinking activity.7